Stock Analysis
Tango Therapeutics, Inc. (TNGX) Stock Analysis
Tango Therapeutics, Inc. (TNGX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Tango Therapeutics, Inc. (TNGX) currently has an AIQ Score of 61/100, indicating a neutral setup. Quality is the strongest factor at 73/100. Risk is the weakest current factor at 38/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
TNGX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $25.50 |
| AIQ Score | 61/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $4.44B |
| P/E Ratio (TTM) | -18.48 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.39 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.61 |
| Volume | 2.71M |
| 52-week range | $7.49-$34.39 |
| RSI 14 | 57.02 |
| 50-Day SMA | $23.53 |
| 200-Day SMA | $22.90 |
| Analyst Price Target | $56.00 |
| Next Earnings | Mar 4, 2027 |
TNGXTango Therapeutics, Inc.
Healthcare / Biotechnology
Relative Leader / Watch
Sector Leader
Latest quote
- Momentum60
- Value—
- Quality73
- Risk resilience38
- Sentiment—
TNGX Stock Analysis Summary
Tango Therapeutics, Inc. (TNGX) currently has an AIQ Score of 61/100, indicating a neutral setup. Quality is the strongest factor at 73/100. Risk resilience is the weakest current factor at 38/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, TNGX has AIQ Score of 61/100 with Quality base of 73/100 and fading Risk resilience at 38/100. Wait for component alignment before adding exposure.
Quality (73/100) leads while Risk resilience (38/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 2.62% stock move · TNGX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is TNGX Bullish or Bearish Right Now?
TNGX currently has a neutral overall setup. Quality is the strongest factor at 73/100, while Risk Resilience is weakest at 38/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 73/100.
- - Price is +8.39% above its 50-day SMA.
- - Analyst target implies +119.61% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (33 vs 8).
- - Risk Resilience is weak at 38/100.
Current Consensus
TNGX's Technical Analysis Consensus is currently Strong Buy, with 33 buy, 5 neutral, and 8 sell votes. TNGX's 14-day RSI is 57.02, which places the stock in a constructive momentum range. TNGX's beta is 1.61, indicating greater market sensitivity than the broad market.
What Changed in TNGX?
The largest recent change in TNGX is AIQ Score moving up by 10.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the TNGX Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
TNGX Decision Framework
Public evidence layers, setup checks, and risk context for Tango Therapeutics, Inc..
Tango Therapeutics, Inc. (TNGX) Stock Analysis
Tango Therapeutics, Inc. has an AIQ Score of 61/100 in a Neutral regime. Quality is strongest at 73/100. Beta is 1.61, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | TNGX is in a Neutral AIQ regime with score 61/100. |
| Signal Conflict | The primary conflict is that quality leads at 73/100 while risk lags at 38/100. |
| Factor Evidence | Momentum 60/100 · Quality 73/100 · Risk 38/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 73/100.
Momentum is 60/100 and RSI (14) is 57.0.
TNGX is in a Neutral regime at 61/100.
Risk factor is 38/100 with beta 1.61 and annual volatility 101.07%.
Current conflict: quality leads at 73/100 while risk lags at 38/100.
TNGX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
TNGX Fundamentals
TNGX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
TNGX Technical Analysis
TNGX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
TNGX Stock Catalysts
Track TNGX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
TNGX Dividend Analysis
TNGX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
TNGX Financial Data
TNGX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
TNGX Risk Analysis
TNGX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
TNGX Stock News
TNGX stock news, market tone, recent headlines, and catalyst context.
TNGX vs Biotechnology Peers
Current peer cohort: TNGX · TRVI · TSHA · TVTX · TWST. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| TNGX Current stock | 61/100 | — | 60/100 | 38/100 | 1.61 | 101.07% | Current |
| TRVI Trevi Therapeutics, Inc. | 63/100 | — | 52/100 | 51/100 | 0.52 | 59.27% | TNGX vs TRVI |
| TSHA Taysha Gene Therapies, Inc. | 35/100 | — | 32/100 | 37/100 | 0.32 | 70.69% | TNGX vs TSHA |
| TVTX Travere Therapeutics, Inc. | 64/100 | 69/100 | 67/100 | 55/100 | 0.87 | 62.28% | TNGX vs TVTX |
| TWST Twist Bioscience Corporation | 64/100 | 58/100 | 84/100 | 32/100 | 1.94 | 84.18% | TNGX vs TWST |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for TNGX: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching TNGX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for TNGX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
TNGX Stock FAQ
What is TNGX stock price today?
Tango Therapeutics, Inc.'s current stock price is $25.50. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is TNGX bullish or bearish right now?
TNGX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is TNGX's market cap?
TNGX's market cap is $4.44B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is TNGX's current P/E ratio?
TNGX's current P/E ratio is -18.48 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is TNGX's RSI?
TNGX's 14-day RSI is 57.02 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is TNGX above its 50-day and 200-day moving averages?
TNGX is 8.39% from its 50-day SMA and 11.37% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is TNGX's next earnings date?
TNGX's next earnings date is currently listed as Mar 4, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does TNGX pay a dividend?
TNGX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.